<DOC>
	<DOCNO>NCT00461578</DOCNO>
	<brief_summary>In 2005-2006 , clinical trial carry test safety , tolerability efficacy combination chlorproguanil-dapsone+artesunate ( CD+A ) : 800 child age 12-59 month uncomplicated P. falciparum malaria randomly allocate AQ+SP CD+A follow day 28 treatment . Adverse event , clinical parasitological outcome record .</brief_summary>
	<brief_title>Tolerability Efficacy CD+A Compared AQ+SP Treatment P.Falciparum Malaria Rwandan Children</brief_title>
	<detailed_description>Between 2001 2006 , interim strategy , Rwanda choose amodiaquine+ sulfadoxine-pyrimethamine ( AQ+SP ) first line anti-malaria treatment . Although clinical response combination relatively good 2001 , since efficacy steadily decline : 2002 proportion successful treatment ( record 28 day PCR-unadjusted ) 83 % ( Rwagacondo et al. , 2003 ) 2003 74 % ( Karema et al. , 2006 ) . Different artemisinin-based combination treatment ( ACTs ) amodiaquine+artesunate ( AQ+AS ) , dihydroartemisinin-piperaquine ( DHAPPQ ) artemether-lumefantrine ( ALN ) test past year possible alternative AQ+SP ( Fanello et al. , 2006 ; Karema et al. , 2006 ) . Chlorproguanil-dapsone ( also know asLapDap ) antifolate combination similar sulfadoxine/pyrimethamine ( SP ) two important feature : ( 1 ) rapidly eliminate therefore exerts less selective pressure resistance-conferring parasite mutation SP ( Winstanley et al. , 1997 ; Nzila et al. , 2000b ) ( 2 ) active SP-resistant form parasite find Africa ( Mutabingwa et al. , 2001a , b ; Kublin et al. , 2002 ) . Moreover , pediatric course treatment LapDap estimate cost $ 0.15 ( Mutabingwa et al. , 2001b ) , make order magnitude less expensive market antimalarial drug chloroquine SP . In 2005-2006 , clinical trial carry test safety , tolerability efficacy combination chlorproguanil-dapsone+artesunate ( CD+A ) : 800 child age 12-59 month uncomplicated P. falciparum malaria randomly allocate AQ+SP CD+A follow day 28 treatment . Adverse event , clinical parasitological outcome record . Based result trial carry NMCP , The Rwandan Ministry Health change first line artemether-lumefantrine ( ALN ) , Coartem® . The drug arrive country October 2006 .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Malaria , Falciparum</mesh_term>
	<mesh_term>Chlorproguanil</mesh_term>
	<mesh_term>Proguanil</mesh_term>
	<mesh_term>Dapsone</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>Age 1259 month ; Weight ≥5 kg ; Monoinfection P. falciparum ; Parasite density 2,000200,000/µL ; Fever ( axillary body temperature = &gt; 37.5C ) history fever precede 24 hour ; Packed Cell Volume ( PCV ) &gt; 21 % . Severe malaria ; Mixed malaria infection ; Any concomitant illness underlying disease ; Known allergy study drug use trial ; Clear history adequate antimalarial treatment previous 72 hour .</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>59 Months</maximum_age>
	<verification_date>April 2007</verification_date>
	<keyword>P.falciparum</keyword>
	<keyword>malaria</keyword>
	<keyword>lapdap+artesunate</keyword>
	<keyword>safety</keyword>
	<keyword>efficay</keyword>
</DOC>